2025
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
Othus M, Kurzrock R, Patel S, Chae Y, Patel S, Sosman J, Snyder Charen A, Rizvi N, LaVallee T, Felquate D, Burton E, Futreal P, Sullivan R, Kluger H, Tawbi H. Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG. Journal Of Clinical Oncology 2025, 43: 2656-2656. DOI: 10.1200/jco.2025.43.16_suppl.2656.Peer-Reviewed Original ResearchOverall survivalMartingale residual plotsAdjuvant settingPD-(L)1Shorter OSNo significant differencePrimary resistanceAssociated with significantly shorter OSHazard ratioHigh-risk resected stagePD-(L)1 inhibitorsImmunotherapy of cancerSignificant differenceConfidence intervalsCox regression modelsClinical trial interpretationAdjuvant cohortAdjuvant pembrolizumabImmunotherapy resistanceLate recurrenceResected stageEarly recurrenceSWOG trialsIO agentsPatient cohort
2021
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply